Related Experiment Video
Updated: Jun 18, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Research progress of malignant peritoneal mesothelioma with paraneoplastic syndrome: A review
Xin-Li Liang1, Xin-Bao Li1, Yu-Bin Fu1
1Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Abstract:
Malignant peritoneal mesothelioma (MPM) is a rare and invasive tumor, and some patients will develop paraneoplastic syndrome (PS) during the course of the disease. This review summarizes PS associated with MPM, focusing on the clinical characteristics and treatment progress in hematological, endocrine, rheumatic, neurological, urinary, and other systems to decrease missed diagnosis and misdiagnosis, help early diagnosis and prompt treatment, and provide guidance for the clinical decision-making of this kind of patients.
Insights
Malignant peritoneal mesothelioma (MPM) can cause paraneoplastic syndromes (PS). This review details PS clinical features and treatments across various systems to improve diagnosis and patient care for MPM patients.
Area of Science:
- Oncology
- Internal Medicine
- Pathology
Background:
- Malignant peritoneal mesothelioma (MPM) is a rare and aggressive malignancy.
- Paraneoplastic syndromes (PS) are systemic manifestations that can occur in MPM patients.
- Accurate diagnosis and timely management of PS in MPM are often challenging.
Purpose of the Study:
- To review and summarize paraneoplastic syndromes associated with malignant peritoneal mesothelioma.
- To focus on the clinical characteristics and treatment progress of PS across multiple organ systems.
- To aid in reducing missed and misdiagnoses, facilitating early detection and prompt treatment.
Main Methods:
- Comprehensive literature review of studies on paraneoplastic syndromes in malignant peritoneal mesothelioma.
- Analysis of clinical characteristics, diagnostic approaches, and therapeutic strategies.
- Categorization of PS based on affected systems (hematological, endocrine, rheumatic, neurological, urinary, etc.).
Main Results:
- PS in MPM patients manifest across diverse systems, including hematological, endocrine, rheumatic, neurological, and urinary.
- Detailed descriptions of the clinical presentations for each type of PS.
- Overview of current treatment advancements and management protocols for these syndromes.
Conclusions:
- Understanding the spectrum of PS in MPM is crucial for accurate diagnosis and effective management.
- This review provides valuable guidance for clinicians in decision-making for MPM patients with PS.
- Early identification and prompt treatment of PS can improve outcomes for patients with malignant peritoneal mesothelioma.
